Viral Titer Improvement via Cell Seeding Density and Media Re-feeding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for improving viral titer in transfection-based bioreactor culture production systems using eukaryotic cells are inefficient, leading to high production costs and limited clinical trial capabilities.
Innovation Solution
The method involves seeding eukaryotic cells at a density of at least 5×10^4 cells/cm² 4 to 5 days prior to harvest, harvesting cells beyond the log phase for transfection, incubating transfection reagents at room temperature, and using a combination of transfection, re-seeding, and media re-feeding steps, including the use of conditioned media and anion-exchange capsules for viral vector capture and concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional transfection-based production methods are used, then production costs are high and clinical trial capabilities are limited, but viral titer improvement is inefficient
Solution Approach 1:
The patent applies parameter changes by optimizing multiple cultivation parameters including seeding density (5×10^4 to 1×10^5 cells/cm²), cell age (4-7 days post-seeding), transfection timing, and media composition (50% conditioned media + 50% fresh media). These parameter optimizations collectively improve viral titer by at least 2-fold while maintaining cost-effective production processes
2Productivity
If cells are harvested during log phase, then cell growth is active, but viral titer production is suboptimal
Solution Approach 1:
The patent applies preliminary action by allowing cells to progress beyond the log phase into the stationary phase before harvesting and transfection. Cells are seeded 4-7 days prior to harvest, ensuring they have completed active growth and are in a more metabolically stable state that enhances transfection efficiency and viral production
3Productivity
If transfection reagents are used at standard conditions, then transfection proceeds normally, but viral titer improvement is limited
Solution Approach 1:
The patent applies parameter changes by incubating transfection reagents at room temperature for 20 minutes before mixing with cells, and by using specific transfection reagent-to-DNA ratios. These modified parameters significantly enhance transfection efficiency and viral titer production compared to standard protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a significant improvement of viral titer by at least 2-fold, optimizing production conditions for clinical-grade vector production and expanding clinical trial capabilities.
Implementation Method 1
capturing viral vectors from cell-free supernatant using an anion-exchange capsule
Implementation Method 2
concentrating captured viral vectors using a Polysulfone (PS) or Polyether (PES) tangential-flow filtration (TFF) module
Data Source
AI summary
The invention relates to methods of improving titer in transfection-based bioreactor culture production or transfection-based production systems using eukaryotic cells.